Unique AI platform to provide eureKARE with a leading edge to help develop and scale its portfolio companies in the microbiome and synthetic biology spaces
eureKARE, a pioneering new company focused on financing and building next generation biotechnology companies in the disruptive fields of the microbiome and synthetic biology, announces an agreement with DNAlytics, a Belgium-based company applying data sciences to healthcare, to develop eureKARE’s proprietary Artificial Intelligence (AI) platform, to support its Biotech start-up studios, eureKABIOME, to be based in France and eureKASYNBIO, to be based in Belgium.
Read More: ATxSG Unveils Exciting Speaker Line-Up That Explores The Intersection Of Technology, Society &…
Contrary to traditional start-up incubation models, which start with novel science and then try to identify a problem to solve with it, eureKARE’s approach flips this on its head. eureKARE is focused on first identifying the unmet need and then engaging the top scientists and researchers to identify an innovative solution, to eventually establish exciting new ventures.
eureKARE’s unique AI platform will support this process, helping the company identify the leading academic researchers, locate new ideas and approaches in development, and help scale existing portfolio companies.
Serge Pampfer, Chief Scientific Officer at eureKARE, commented: “This new and powerful AI tool will provide eureKARE with a competitive edge and be the most efficient way for us to support and build out our compelling portfolio of companies in the synthetic biology and microbiome spaces. DNAlytics was our preferred partner for this exciting next generation AI platform due to its extensive experience supporting healthcare AI and we look forward to working with them.”
Rodolphe Besserve, Chief Executive Officer at eureKARE, echoed: “eureKARE was founded to build bridges between academia and big pharma, and we believe this new AI platform will help us to identify and develop new exciting ventures faster and in a more targeted way.”
Thibault Helleputte, co-founder and Chief Executive Officer of DNAlytics, added: “This innovative project will demonstrate the central role that AI is increasingly playing in the identification and prioritization of promising life sciences projects. We are delighted to support the development of eureKARE’s AI platform and to develop a novel way to connect top scientists with exciting research projects, and visionary investors.”
Read More: Convert Group Study: COVID-19 Drew More Than 2.7 Billion Visits To Global EPharmacies In 96…
